FDA panel considers a first-of-its-kind flu vaccine using mRNA technology
Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and older
US health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic.
Moderna is seeking Food and Drug Administration (FDA) approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season.
Continue reading...
이 뉴스, 독자들은 어떻게 느꼈나요?
첫 반응을 남겨보세요로그인하면 감정 반응에 참여할 수 있어요.
공식 발표 ↔ 진영별 보도
Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
Advisory Committee; Science Board to the Food and Drug Administration; Renewal